✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Netupitant is an investigational drug.
There have been 16 clinical trials for Netupitant. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2021.
The most common disease conditions in clinical trials are Vomiting, Nausea, and Breast Neoplasms. The leading clinical trial sponsors are Helsinn Healthcare SA, National Cancer Institute (NCI), and Consorzio Oncotech.
There are one hundred and forty-seven US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Netupitant
|Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)||Helsinn Healthcare SA||Phase 4|
|Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer||Instituto Brasileiro de Controle do Cancer||Phase 2|
|Low Dose Aprepitant for Patients Receiving Carboplatin||Jacobi Medical Center||Phase 2|
Top disease conditions for Netupitant
Top clinical trial sponsors for Netupitant
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Netupitant||See Plans and Pricing||Crystalline forms of fosnetupitant||Helsinn Healthcare SA (Lugano/Pazzallo, CH)||See Plans and Pricing|
|Netupitant||See Plans and Pricing||Cyclohexyl pyridine derivative||KISSEI PHARMACEUTICAL CO., LTD. (Matsumoto, Nagano, JP)||See Plans and Pricing|
|Netupitant||See Plans and Pricing||.beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof||Quadriga Biosciences, Inc. (Los Altos, CA)||See Plans and Pricing|
|Netupitant||See Plans and Pricing||Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same||STC.UNM (Albuquerque, NM) Sandia Corporation (Albuquerque, NM)||See Plans and Pricing|
|Netupitant||See Plans and Pricing||Method for cancer cell reprogramming||STC.UNM (Albuquerque, NM)||See Plans and Pricing|
|Netupitant||See Plans and Pricing||Bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use||The Trustees of The University of Pennsylvania (Philadelphia, PA)||See Plans and Pricing|
|Netupitant||See Plans and Pricing||Estrogen-related receptor alpha based protac compounds and associated methods of use||Yale University (New Haven, CT) Arvinas, Inc. (New Haven, CT)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Netupitant||Australia||AU2016335060||2035-10-06||See Plans and Pricing|
|Netupitant||Canada||CA2996466||2035-10-06||See Plans and Pricing|
|Netupitant||China||CN108137626||2035-10-06||See Plans and Pricing|
|Netupitant||European Patent Office||EP3359547||2035-10-06||See Plans and Pricing|
|Netupitant||Japan||JP2018531249||2035-10-06||See Plans and Pricing|
|Netupitant||Japan||JP6880009||2035-10-06||See Plans and Pricing|
|Netupitant||South Korea||KR20180064453||2035-10-06||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|